Vallon Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About Vallon Pharmaceuticals, Inc.

Vallon Pharmaceuticals, Inc. was a U.S.-listed biopharmaceutical company that traded on the NASDAQ market in the United States before its April 2023 merger with GRI Bio, Inc. The company was incorporated in Delaware on January 11, 2018, and completed its initial organization and capitalization in June 2018. Its historical headquarters were in Philadelphia, Pennsylvania, and its corporate profile was that of an early-stage specialty biotech focused on proprietary drug development rather than on established commercial sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1824293/000110465920117717/tm2030737-1_s1.htm?utm_source=openai)) Vallon’s lead program was ADAIR, a proprietary abuse-deterrent oral formulation of immediate-release dextroamphetamine, designed for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. In investor materials, the company positioned ADAIR as a differentiated stimulant product intended to address a key safety and misuse issue in the ADHD market. As a clinical-stage biotech, Vallon’s value proposition depended primarily on development milestones, regulatory progress, and eventual commercialization success, rather than on current product revenue. SEC disclosures also reflected the typical risks of a pre-commercial pharmaceutical company, including ongoing operating losses, financing needs, and going-concern uncertainty. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1824293/000110465921003928/tm2030737-7_s1a.htm?utm_source=openai)) From a competitive standpoint, Vallon operated in a narrow but potentially attractive niche at the intersection of ADHD therapeutics, stimulant abuse-deterrent technology, and formulation innovation. The company’s potential differentiation came from product design and intellectual-property protection, but it faced the usual biotech execution risks: clinical development uncertainty, regulatory review, funding dependence, and competition from both branded and generic stimulant therapies. For equity investors, that meant the stock profile was driven more by binary catalysts and pipeline milestones than by stable operating fundamentals. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1824293/000110465921003928/tm2030737-7_s1a.htm?utm_source=openai)) A crucial current-context point is that Vallon no longer exists as an independent listed issuer. In April 2023, Vallon completed its merger with GRI Bio, Inc., and the combined company adopted the name GRI Bio, Inc. Subsequent SEC filings refer to the legacy Vallon structure only as part of the merger history. More recent filings show the company’s principal executive offices in La Jolla, California, which underscores that the legacy Vallon entity has been folded into the post-merger organization. ([globenewswire.com](https://www.globenewswire.com/news-release/2023/04/21/2652134/0/en/Vallon-Pharmaceuticals-Completes-Merger-with-GRI-Bio-Inc.html?utm_source=openai)) In practical terms, Vallon Pharmaceuticals is best understood as a former NASDAQ-listed U.S. micro-cap biotech whose business centered on a single differentiated CNS asset, ADAIR, and whose corporate identity was later absorbed into GRI Bio. For French-speaking investors in Europe, the key takeaway is that references to Vallon today are mainly historical or documentary: they are relevant for reading SEC filings, insider transactions, and merger-related disclosures, but not as evidence of an ongoing standalone operating company. ([globenewswire.com](https://www.globenewswire.com/news-release/2023/04/21/2652134/0/en/Vallon-Pharmaceuticals-Completes-Merger-with-GRI-Bio-Inc.html?utm_source=openai))